



In the Specification:

Please replace the Sequence Listing with that attached herewith.

**REMARKS**


Enclosed please find:

- (i) a nucleotide and/or amino acid listing in a computer readable and paper forms; and
- (ii) a copy of the Notice.

***Statements***

The content of the paper and computer readable form are the same and include no new matter.

Respectfully submitted,




Sol Sheinbein  
Registration No. 25,457

Date: February 23, 2004

***Encl.:***

a nucleotide and/or amino acid listing in a computer readable form; and  
a copy of the Notice.



UNITED STATES PATENT AND TRADEMARK OFFICE

21982

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/873,415	06/05/2001	Nathan Karin	01/21982	1850
7590 01/28/2004				
G.E. EHRLICH (1995) LTD. c/o ANTHONY CASTORINA SUITE 207 2001 JEFFERSON DAVIS HIGHWAY ARLINGTON, VA 22202			EXAMINER SCHWADRON, RONALD B	
			ART UNIT 1644	PAPER NUMBER

DATE MAILED: 01/28/2004

2

Please find below and/or attached an Office communication concerning this application or proceeding.

URGENT

28 FEB 2004



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER
----------

ART UNIT	PAPER
----------	-------

200401

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

*Regarding the antisense primer sequence (SEQ ID NO:3) disclosed in the specification (page 71) said sequence is disclosed in the sequence listing in the 5' to 3' direction as per required by the sequence rules. However, the sequence listing needs to disclose that said sequence is a reverse or "antisense" sequence, because said sequence is a 5' to 3' representation of an antisense sequence (eg. normally represented in the 3' to 5' direction). Thus section <223> needs to be changed in the CRF and paper copy of the sequence listing to indicate that said sequence is antisense.*

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (571)272-0851. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Ron Schwadron, Ph.D.  
Art Unit 1644  
1/25/04

RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1860 1644